ST3GAL2

Across TCGA pan-cancer cohorts, ST3GAL2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ST3GAL2 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ST3GAL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ST3GAL2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, LIHC, and TGCT are the cancer types where ST3GAL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.253	0.680	<.001	27	view →
LIHC	OS	Median	All	0.059	0.783	<.001	12	view →
TGCT	DFS	Median	All	0.081	0.801	.005	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SCLC	OS	Median	All	0.219	0.706	.011	6	view →
UCEC	DFS	Median	All	1.000	0.620	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ST3GAL2–STAD (OS)

Open the STAD breakdown →